Happy New Year, Business of Biotechers!

I came home from San Francisco, where I recorded a dozen episodes of the podcast on-site with some pretty great execs, on a Friday. Woke up the next morning with a scratchy throat. Achy body and a positive COVID test the next day. Shocker, right? Too much JPM Week evening revelry, I suppose. I suspect I'm one of many.

Was it worth it? I'll let you be the judge. Over the next several weeks, we'll air episodes recorded on the trip with the leaders of Generate:Biomedicines , Ampersand Biomedicines , Triumvira Immunologics, Inc. , bit.bio, and a whole lot more. Everyone's favorite CFO, Allan Shaw , makes an appearance, too. To a one, the execs I met with shared fact-based evidence of a positive turn for biotech in 2024. Stay tuned!

In the meantime, here's what's hot in the business of biotech, from the Life Science Connect family.

Thanks for listening,

Matthew Pillar , Business of Biotech host and chief editor, Bioprocess Online

Biotech Beat

Up, Up, & Away For ADCs

In this article published at Life Science Leader , our own Tyler Menichiello covers one of the biopharma bright spots that's fueling the optimism for a biotech turnaround that was palpable a the JP Morgan Healthcare Conference earlier this month. DeciBio 's Joe Daccache, Ph.D. and Rebecca Bair bring the numbers, a whopping 76 ADC deals made in 2023, and offer some projections for continued ADC advances in 2024. READ NOW →

Q&A with GSK Director of CMC Policy and Advocacy Ben Stevens

With growing therapeutic complexity comes the need for CMC agility, and with that agility comes acceptance of change. Admittedly, "change management" and "efficiencies" are words that don't often play well together. But, in this Q&A with Bioprocess Online 's Jon O'Connell , 荷商葛蘭素史克藥廠 Director of CMC Policy and Advocacy Benjamin Stevens offers sound direction on navigating change management in a way that minimizes disruption and timeline impact. READ NOW →

Clinical Comprehension In 2024

Clinical Leader Executive Editor Abby Proch relentlessly interviewed a gaggle of clinical trial experts to churn out a four-part series on just about everything a clinical-stage biotech will need to be aware of in 2024. It's a comprehensive take on AI, DEI, precision medicine, decentralized trials, hot modalities, accelerated approvals, and a whole lot more. Come for?part one, stay for the series.

RNA Anything & Everything

Life Science Connect launched some new sites in 2024, and here's one of them. My friend Anna Rose Welch (ARW) is among our greatest assets, and she's heading up our new Advancing RNA initiative. Stick any letter, shape, or word in front of (or after) "RNA" (m, s, si, micro, circular, antisense, interference — you get the picture) and its implications on the ATMP space are covered here, in a thoughtful and unique ARW kind of way. Bookmark and subscription-worthy, I promise. READ NOW →

Quotes Of The Month

"If you're doing anything on the cutting edge of science, most of what you do is wrong. Learning how to deal with that is part of being a good scientist. That also applies well in the world of business. You make mistakes, and then you correct."

― Neela Patel , Ph.D., Chief Business Officer, Bonum Therapeutics ,?Episode 180

"Being naive to [launching a biotech] was advantageous, because if I'd known the complexity of it all, if someone had sat me down on day one and said, 'oh, this is what's required,' I would have thought, 'ahhh no.'"

― Sam Costello , Ph.D., Managing Director & Co-founder, BiomeBank ,?Episode 181

"Those companies that are pre-commercial, they've all paid the price of having their future discounted very, very aggressively. That means that, in the eye of the economist, the technologies are just not worth as much."

― John Leonard , M.D., CEO, Intellia Therapeutics, Inc. ,?Episode 184

Advancing RNA | Bioprocess Online | Cell & Gene | Clinical Leader | Drug Delivery | Life Science Leader | Pharmaceutical Online | Outsourced Pharma

? Copyright 2024 Vertmarkets, Inc. 5340 Fryling Rd Suite 100, Erie, PA 16510